InnovAge free cash flow INNV
Cash from operations less capital spending, by quarter and over the last twelve months, from 2020.
- Last 12 months, to Jun 30, 2026
- $50.4M
- Latest quarter, Q4 FY26
- $17M
- +85% on a year earlier
- Fiscal year 2026
- $50.4M
- +89% on the year before
InnovAge's free cash flow was $50.4M over the twelve months to Jun 30, 2026, up 89% on a year earlier.
In its latest quarter, Q4 FY26, it was $17M, up 85% on the same quarter a year before.
Free cash flow over time
Fiscal year by fiscal year
| Fiscal year | Free cash flow | Change |
|---|---|---|
| FY2026 | $50.4M | +89% |
| FY2025 | $26.6M | n/a |
| FY2024 | −$44.8M | n/a |
| FY2023 | −$3.1M | n/a |
| FY2022 | −$10.9M | n/a |
| FY2021 | −$25.1M | n/a |
| FY2020 | n/a | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | Free cash flow | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q4 FY26 | $17M | +85% | $50.4M | |
| Q3 FY26 | $14.5M | −33% | $42.6M | |
| Q2 FY26 | $19M | +251% | $49.8M | |
| Q1 FY26 | −$153K | n/a | $36.2M | |
| Q4 FY25 | $9.2M | n/a | $26.6M | |
| Q3 FY25 | $21.7M | +611% | $16M | |
| Q2 FY25 | $5.4M | n/a | −$2.7M | |
| Q1 FY25 | −$9.7M | n/a | −$19M | |
| Q4 FY24 | −$1.4M | −116% | −$44.8M | |
| Q3 FY24 | $3.1M | −87% | −$34.3M | |
| Q2 FY24 | −$10.9M | n/a | −$12.9M | |
| Q1 FY24 | −$35.6M | −751% | −$44.1M |
Against its peers
Companies in Medical - Care Facilities nearest InnovAge's size, closest first, today.
| Company | Free cash flow yield |
|---|---|
| INNVInnovAge | 3.9% |
| USPHU S Physical Therapy | 4.8% |
| PNTGPennant | 2.4% |
| OMDAOmada Health | 2.0% |
| ARDTArdent Health | 17.6% |
| HCSGHealthcare Services | 8.6% |
| PGNYProgyny | 8.0% |
| ADUSAddus HomeCare | 6.8% |
| MDPediatrix Medical | 9.6% |
| PRVAPrivia Health | n/m |
| AVAHAveanna Healthcare | 5.4% |
| Peer median | 6.8% |
Where InnovAge ranks
What the free cash flow tells you
Cash from operations minus capital spending. The cash the company could hand back or reinvest.
Seasonal and lumpy quarter to quarter. The TTM view is the one to trust.
More on InnovAge
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.